| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | CKLFSF6; PRO2219 |
| WB Predicted band size | 20 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human CMTM6 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于CMTM6抗体的代表性文献(简要概括)：
1. **文献名称**：CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
**作者**：Burr ML, et al.
**摘要**：该研究揭示CMTM6通过结合并稳定PD-L1蛋白，调控肿瘤细胞表面PD-L1水平，影响T细胞介导的抗肿瘤免疫反应。研究中使用CMTM6抗体进行免疫共沉淀和免疫印迹验证相互作用。
2. **文献名称**：CMTM6 is a negative regulator of PD-L1 expression in macrophages
**作者**：Mezzadra R, et al.
**摘要**：文章发现CMTM6在巨噬细胞中通过泛素化途径调控PD-L1降解，使用CMTM6特异性抗体通过流式细胞术和免疫荧光证实其与PD-L1的共定位，为免疫检查点调控提供新机制。
3. **文献名称**：CMTM6 expression correlates with poor prognosis and tumor immune infiltration in hepatocellular carcinoma
**作者**：Kim HR, et al.
**摘要**：该研究利用CMTM6抗体进行免疫组化分析，发现肝癌组织中CMTM6高表达与PD-L1水平正相关，且与患者预后不良及CD8+ T细胞浸润减少相关，提示其作为免疫治疗生物标志物的潜力。
注：以上为基于近年研究趋势的概括性描述，实际文献细节需通过PubMed等数据库核对原文。
CMTM6 (CKLF-like MARVEL transmembrane domain-containing 6) is a protein belonging to the MARVEL domain-containing family, implicated in regulating membrane protein stability and trafficking. It gained significant attention due to its role in stabilizing programmed death-ligand 1 (PD-L1), a key immune checkpoint molecule exploited by cancer cells to evade T-cell-mediated destruction. CMTM6 binds to PD-L1. preventing its lysosomal degradation and maintaining its cell surface expression, thereby modulating tumor immune evasion and response to anti-PD-1/PD-L1 therapies.
Antibodies targeting CMTM6 are essential tools for studying its expression, interaction networks, and functional roles in cancer biology and immunology. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence to quantify CMTM6 levels in tumor tissues or cell lines. Research utilizing CMTM6 antibodies has revealed its overexpression in various cancers, correlating with poor prognosis and therapeutic resistance. Additionally, CMTM6 antibodies help explore its broader roles beyond PD-L1 regulation, including involvement in receptor signaling and membrane protein dynamics.
As the interplay between CMTM6 and immune checkpoints becomes clearer, CMTM6 antibodies also hold potential for developing combination therapies to enhance immunotherapy efficacy. Their application continues to advance understanding of tumor microenvironment regulation and immune escape mechanisms.
×
